Biocon Ltd. is betting the long remission time and reduced opportunistic infections associated with its Alzumab itolizumab will pull doctors away from biologics with better efficacy in psoriasis.

The company has long maintained that the first-in-class biologic has a safety advantage over competing psoriasis biologics. Now the long-term data it is collecting from its psoriasis trials are providing a new selling point for the drug - duration of remission.